Shanghai General Hospital

Company snapshot

Shanghai General Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Non Small Cell Lung Cancer. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Shanghai General Hospital. Not investment advice.

• What is Shanghai General Hospital?

  Shanghai General Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Non Small Cell Lung Cancer. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.go

• Is Shanghai General Hospital publicly traded?

  Shanghai General Hospital appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Shanghai General Hospital develop or market?

  We link 2 drug profile(s) where Shanghai General Hospital is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/shanghai-general-hospital-shanghai-jiao-tong-university-school-of-medicine#company-drugs.

• What are the latest developments for Shanghai General Hospital?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Shanghai General Hospital focus on?

  Shanghai General Hospital focuses on Non Small Cell Lung Cancer based on our analysis of their pipeline programs and drug development activities.